Latest On Cara Therapeutics, Inc (CARA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-18 18:10 EST | News | UK drug pricing watchdog backs use of Cara, Vifor's Kapruvia in NHS | N/A |  |
| 2023-05-15 21:49 EST | News | Cara Therapeutics GAAP EPS of -$0.49 beats by $0.03, revenue of $6.17M beats by $1.19M | N/A | |
| 2023-05-15 21:48 EST | News | Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-14 18:20 EST | News | Cara Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-04-24 04:39 EST | News | Cara Therapeutics Struggles With Financial Position And Market Challenges: Maintain 'Sell' | N/A | |
| 2023-03-13 11:13 EST | News | Cara Therapeutics: Looking To Place A Bid After A Big Miss On Earnings | N/A | |
| 2023-03-10 21:06 EST | News | Cara, Iovance, and Karyopharm among biotechs with no exposure to SVB (updated) | N/A | |
| 2023-03-08 23:24 EST | News | Cara Therapeutics downgraded at BofA on sales forecast for Korsuva | N/A | |
| 2023-03-07 02:16 EST | News | Cara Therapeutics GAAP EPS of -$0.56 misses by $0.20, revenue of $3.26M misses by $11.24M | N/A | |
| 2023-03-07 02:16 EST | News | Cara Therapeutics plummets 29% on quarterly misses; enough cash to operate to H1 2024 | N/A | |
| 2023-03-07 02:16 EST | News | Cara Therapeutics, Inc. (CARA) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-21 22:25 EST | News | Cara Therapeutics: Difelikefalin Struggles To Stand Out With Uncertain Prospects | N/A | |
| 2023-01-20 16:07 EST | News | Cara Therapeutics (CARA) Presents At 41st Annual Healthcare Conference - Slideshow | N/A | |
| 2022-11-26 05:07 EST | News | Neutral On Cara Therapeutics | N/A | |
| 2022-11-08 09:23 EST | News | Cara Therapeutics, Inc. (CARA) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-07 16:12 EST | News | Cara Therapeutics Q3 2022 Earnings Preview | N/A | |
| 2022-11-07 16:10 EST | News | Cara Therapeutics GAAP EPS of -$0.43 beats by $0.01, revenue of $10.81M beats by $1.95M | N/A | |
| 2022-10-11 00:04 EST | News | SWK Holdings unit receives $5M payment from Cara Therapeutics | N/A | |
| 2022-09-28 16:20 EST | News | Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients | N/A | |
| 2022-09-12 14:59 EST | News | Cara Therapeutics hires new finance chief | N/A | |
| 2022-09-01 20:25 EST | News | Cara Therapeutics: All Eyes On Korsuva Launch Metrics | N/A | |
| 2022-08-19 16:30 EST | News | Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients | N/A | |
| 2022-08-08 23:14 EST | News | Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M | N/A | |
| 2022-08-08 23:14 EST | News | Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-07 21:00 EST | News | Cara Therapeutics Q2 2022 Earnings Preview | N/A | |
| 2022-06-30 07:34 EST | News | Cara reaches main goal in mid-stage trial for pruritus therapy in nerve disorder | N/A | |
| 2022-06-24 22:59 EST | News | Calls A Much Safer Way To Buy Cara Therapeutics | N/A | |
| 2022-05-11 01:15 EST | News | Cara Therapeutics stock soars after Q1 earnings beat, optimism over Korsuva U.S. launch | N/A | |
| 2022-05-10 03:12 EST | News | Cara Therapeutics GAAP EPS of -$0.52 beats by $0.10, revenue of $4.79M beats by $2.53M | N/A | |
| 2022-05-10 03:11 EST | News | Cara Therapeutics, Inc. (CARA) CEO Chris Posner on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-09 07:21 EST | News | Cara Therapeutics Q1 2022 Earnings Preview | N/A | |
| 2022-04-02 14:13 EST | News | Cara Therapeutics (CARA) Investor Presentation - Slideshow | N/A | |
| 2022-03-28 16:40 EST | News | Cara Therapeutics Korsuva improves itch biomarkers in eczema patients in study | N/A | |
| 2022-03-22 19:29 EST | News | Taking A (Speculative) Position In Cara Therapeutics | N/A | |
| 2022-03-15 00:51 EST | News | Cara price target lowered at H.C. Wainwright on pricing concerns for pruritus drug | N/A | |
| 2022-03-01 22:19 EST | News | Cara Therapeutics GAAP EPS of -$0.63 misses by $0.11, revenue of $0.82M misses by $0.43M | N/A | |
| 2022-03-01 22:19 EST | News | Cara Therapeutics down 8% after hours following Q4 2021 earnings misses | N/A | |
| 2022-03-01 22:19 EST | News | Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-01 04:02 EST | News | Cara Therapeutics Q4 2021 Earnings Preview | N/A | |
| 2022-02-26 00:38 EST | News | Cara, Vifor's Kapruvia gets EMA panel backing to treat itch in hemodialysis patients | N/A | |
| 2021-12-25 19:56 EST | News | Cara Therapeutics: De-Risked And Extremely Attractive | N/A | |
| 2021-12-20 23:32 EST | News | Cara Therapeutics wins CMS grants for newly approved pruritus therapy | N/A | |
| 2021-12-10 11:39 EST | News | SWK Holdings' subsidiary, Enteris BioPharma received $5M milestone payment from Cara Therapeutics | N/A | |
| 2021-11-09 05:10 EST | News | Cara Therapeutics EPS beats by $0.40, beats on revenue | N/A | |
| 2021-11-09 05:10 EST | News | Cara Therapeutics shares jump 10% on Q3 earnings beat, cash position update | N/A | |
| 2021-11-09 05:10 EST | News | Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-08 08:50 EST | News | Cara Therapeutics Q3 2021 Earnings Preview | N/A | |
| 2021-11-03 09:20 EST | News | Cara Therapeutics rises on new CEO appointment | N/A | |
| 2021-11-01 16:25 EST | News | Checking Back In On Cara Therapeutics | N/A | |
| 2021-10-31 03:12 EST | News | Ocugen among top healthcare gainers this week; Alzheimer’s setback hurts Cortexyme | N/A | |
About Cara Therapeutics, Inc (CARA):
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
General
- Name Cara Therapeutics, Inc
- Symbol CARA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 80
- Last Split Factor1:2
- Last Split Date2014-01-16
- Fiscal Year EndDecember
- IPO Date2014-01-31
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryBiotechnology
- Web URLhttp://www.caratherapeutics.com
View More
Valuation
- Trailing PE 108.02
- Price/Sales (Trailing 12 Mt.) 6.85
- Price/Book (Most Recent Quarter) 3.87
- Enterprise Value Revenue 5.9
- Enterprise Value EBITDA 140.68
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.92
- Next Year EPS Estimate -$0.83
- Next Quarter EPS Estimate -$0.51
- Profit Margin 6%
- Operating Margin 4%
- Return on Assets 1%
- Return on Equity 4%
- Revenue 135.08 million
- Earnings Per Share $0.18
- Revenue Per Share $2.85
- Gross Profit 27.23 million
- Quarterly Earnings Growth 2384.8%
View More
Highlights
- Market Capitalization 953.64 million
- EBITDA 5.59 million
- PE Ratio -0.32
- Analyst Target Price $35.13
- Book Value Per Share $4.99
View More
Share Statistics
- Shares Outstanding 49.88 million
- Shares Float 41.84 million
- % Held by Insiders 1047%
- % Held by Institutions 68.72%
- Shares Short 3.07 million
- Shares Short Prior Month 2.8 million
- Short Ratio 5.53
- Short % of Float 7%
- Short % of Shares Outstanding 6%
View More
Technicals
- Beta 1.36
- 52 Week High $22.6
- 52 Week Low $10.54
- 50 Day Moving Average 19.35
- 200 Day Moving Average 16.14
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Cara Therapeutics, Inc (CARA) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Cara Therapeutics, Inc (CARA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $112.09 million | $1.59 | $0.22 | 639.53% |
| 2020-09-30 | 2020-11-09 | $N/A | -$0.35 | -$0.59 | 40.88% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.54 | -$0.63 | 14.62% |
| 2020-03-31 | 2020-05-11 | $8.09 million | -$0.62 | -$0.60 | -3.33% |
| 2019-12-31 | 2020-02-27 | $4.51 million | -$0.61 | -$0.68 | 10.48% |
| 2019-09-30 | 2019-11-05 | $5.79 million | -$0.74 | -$0.59 | -25.06% |
| 2019-06-30 | 2019-08-07 | $5.21 million | -$0.58 | -$0.61 | 4.24% |
| 2019-03-31 | 2019-05-07 | $4.38 million | -$0.56 | -$0.61 | 7.59% |
| 2018-12-31 | 2019-03-12 | $5.53 million | -$0.52 | -$0.59 | 11.86% |
| 2018-09-30 | 2018-11-06 | $5.06 million | -$0.51 | -$0.48 | -5.52% |
| 2018-06-30 | 2018-08-07 | $2.87 million | -$0.52 | -$0.50 | -3.17% |
| 2018-03-31 | 2018-05-09 | $N/A | -$0.51 | -$0.47 | -8.05% |
| 2017-12-31 | 2018-03-15 | $911000 | -$0.43 | -$0.39 | -10.65% |
| 2017-09-30 | 2017-11-02 | $N/A | -$0.38 | -$0.35 | -7.34% |
| 2017-06-30 | 2017-08-03 | $-911000 | -$0.29 | -$0.61 | 52.33% |
| 2017-03-31 | 2017-05-04 | $911000 | -$0.81 | -$0.73 | -10.96% |
| 2016-12-31 | 2017-03-09 | $79000 | -$0.81 | -$0.49 | -65.88% |
| 2016-09-30 | 2016-11-03 | $-72000 | -$0.42 | -$0.47 | 11.45% |
| 2016-06-30 | 2016-08-04 | $79000 | -$0.48 | -$0.41 | -18.02% |
| 2016-03-31 | 2016-05-05 | $7000 | -$0.39 | -$0.40 | 3.11% |
| 2015-12-31 | 2016-03-10 | $1.36 million | -$0.35 | -$0.34 | -3.46% |
| 2015-09-30 | 2015-11-09 | $2.44 million | -$0.19 | -$0.27 | 29.63% |
| 2015-06-30 | 2015-08-10 | $874000 | -$0.25 | -$0.24 | -4.17% |
| 2015-03-31 | 2015-05-12 | $489000 | -$0.21 | -$0.27 | 22.22% |
| 2014-12-31 | 2015-03-26 | $914000 | -$0.18 | -$0.30 | 40% |
| 2014-09-30 | 2014-11-10 | $1.13 million | -$0.29 | -$0.22 | -31.82% |
| 2014-06-30 | 2014-08-07 | $960000 | -$0.16 | -$0.22 | 27.27% |
| 2014-03-31 | 2014-05-12 | $178000 | -$0.22 | -$0.15 | -46.67% |
| 2013-12-31 | 2014-03-27 | $973000 | -$0.49 | -$0.18 | -172.22% |
Cara Therapeutics, Inc (CARA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Cara Therapeutics, Inc (CARA) Chart:
Cara Therapeutics, Inc (CARA) News:
Below you will find a list of latest news for Cara Therapeutics, Inc (CARA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Cara Therapeutics, Inc (CARA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.05 | CALL | 0 | 1319 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.06 | CALL | 0 | 80 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0.1 | CALL | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 1.6 | PUT | 0 | 69 | 425.99 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 456.15 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 609.91 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 544.38 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 376.58 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 367.05 | TRUE | 0 | 0 |
| 2024-08-16 | 2.5 | 0.05 | CALL | 0 | 1554 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 5 | 0.1 | CALL | 0 | 112 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 2.5 | 1.6 | PUT | 0 | 2 | 180.88 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 4.2 | PUT | 0 | 0 | 321.7 | TRUE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | PUT | 0 | 0 | 285.1 | TRUE | 0 | 0 |
| 2024-11-15 | 2.5 | 0.13 | CALL | 0 | 99 | 168.42 | FALSE | 0 | 0 |
| 2024-11-15 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 2.5 | 1.7 | PUT | 0 | 1 | 199.23 | TRUE | 0 | 0 |
| 2024-11-15 | 5 | 4.2 | PUT | 4 | 1 | 229.46 | TRUE | 4.2 | 0 |
| 2024-11-15 | 7.5 | 0 | PUT | 0 | 0 | 263.09 | TRUE | 0 | 0 |
Latest CARA Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 44 | $7.725 |
| Jun 13, 2022 7:59 PM EST | 10 | $7.74 |
| Jun 13, 2022 7:59 PM EST | 2 | $7.74 |
| Jun 13, 2022 7:59 PM EST | 56 | $7.74 |
| Jun 13, 2022 7:59 PM EST | 100 | $7.74 |
Cara Therapeutics, Inc (CARA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120040373/0001209191-20-040373-index.htm |
| 2019-03-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1346830/000000000019005518/0000000000-19-005518-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1346830/000008025519002656/0000080255-19-002656-index.htm |
| 2019-12-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1346830/000008025519003014/0000080255-19-003014-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1346830/000008025520001259/0000080255-20-001259-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1346830/000009375119000223/0000093751-19-000223-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1346830/000009375120000483/0000093751-20-000483-index.htm |
| 2019-02-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1346830/000021545719003072/0000215457-19-003072-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1346830/000083423720004846/0000834237-20-004846-index.htm |
| 2019-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465919060038/0001104659-19-060038-index.htm |
| 2019-11-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465919065851/0001104659-19-065851-index.htm |
| 2019-11-20 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1346830/000110465919065889/0001104659-19-065889-index.htm |
| 2019-12-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465919069243/0001104659-19-069243-index.htm |
| 2019-12-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465919072710/0001104659-19-072710-index.htm |
| 2019-12-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465919075308/0001104659-19-075308-index.htm |
| 2020-01-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920003626/0001104659-20-003626-index.htm |
| 2020-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920026171/0001104659-20-026171-index.htm |
| 2020-02-28 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1346830/000110465920026349/0001104659-20-026349-index.htm |
| 2020-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920037982/0001104659-20-037982-index.htm |
| 2020-04-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920049009/0001104659-20-049009-index.htm |
| 2020-04-22 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1346830/000110465920049737/0001104659-20-049737-index.htm |
| 2020-04-22 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1346830/000110465920049743/0001104659-20-049743-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920059541/0001104659-20-059541-index.htm |
| 2020-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920070389/0001104659-20-070389-index.htm |
| 2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920073982/0001104659-20-073982-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920078412/0001104659-20-078412-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920092721/0001104659-20-092721-index.htm |
| 2020-08-11 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920093298/0001104659-20-093298-index.htm |
| 2020-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920111159/0001104659-20-111159-index.htm |
| 2020-10-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000110465920116235/0001104659-20-116235-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1346830/000117152020000048/0001171520-20-000048-index.htm |
| 2018-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000119312518319575/0001193125-18-319575-index.htm |
| 2019-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000119312519071928/0001193125-19-071928-index.htm |
| 2019-03-15 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1346830/000119312519076767/0001193125-19-076767-index.htm |
| 2019-03-15 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1346830/000119312519076784/0001193125-19-076784-index.htm |
| 2019-04-02 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1346830/000119312519095709/0001193125-19-095709-index.htm |
| 2019-04-24 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1346830/000119312519117139/0001193125-19-117139-index.htm |
| 2019-04-24 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1346830/000119312519117144/0001193125-19-117144-index.htm |
| 2019-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000119312519139646/0001193125-19-139646-index.htm |
| 2019-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000119312519158835/0001193125-19-158835-index.htm |
| 2019-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000119312519166293/0001193125-19-166293-index.htm |
| 2019-07-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000119312519193211/0001193125-19-193211-index.htm |
| 2019-07-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000119312519201236/0001193125-19-201236-index.htm |
| 2019-07-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1346830/000119312519201291/0001193125-19-201291-index.htm |
| 2019-07-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1346830/000119312519202585/0001193125-19-202585-index.htm |
| 2019-07-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000119312519205422/0001193125-19-205422-index.htm |
| 2019-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000119312519215333/0001193125-19-215333-index.htm |
| 2019-08-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1346830/000119312519225621/0001193125-19-225621-index.htm |
| 2019-09-09 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1346830/000119312519240408/0001193125-19-240408-index.htm |
| 2020-10-23 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1346830/000119312520275447/0001193125-20-275447-index.htm |
| 2018-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919118057307/0001209191-18-057307-index.htm |
| 2018-11-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919118058944/0001209191-18-058944-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919118061248/0001209191-18-061248-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919118061253/0001209191-18-061253-index.htm |
| 2018-12-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919118064402/0001209191-18-064402-index.htm |
| 2018-12-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919118064403/0001209191-18-064403-index.htm |
| 2018-12-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919118064404/0001209191-18-064404-index.htm |
| 2018-12-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919118064405/0001209191-18-064405-index.htm |
| 2019-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119000403/0001209191-19-000403-index.htm |
| 2019-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119000404/0001209191-19-000404-index.htm |
| 2019-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119000405/0001209191-19-000405-index.htm |
| 2019-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119000406/0001209191-19-000406-index.htm |
| 2019-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119001924/0001209191-19-001924-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119007341/0001209191-19-007341-index.htm |
| 2019-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119014161/0001209191-19-014161-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119015839/0001209191-19-015839-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119016647/0001209191-19-016647-index.htm |
| 2019-03-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119018214/0001209191-19-018214-index.htm |
| 2019-03-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119018218/0001209191-19-018218-index.htm |
| 2019-03-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119018220/0001209191-19-018220-index.htm |
| 2019-03-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119018222/0001209191-19-018222-index.htm |
| 2019-03-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119019509/0001209191-19-019509-index.htm |
| 2019-03-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119019712/0001209191-19-019712-index.htm |
| 2019-05-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033516/0001209191-19-033516-index.htm |
| 2019-05-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033517/0001209191-19-033517-index.htm |
| 2019-05-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033518/0001209191-19-033518-index.htm |
| 2019-05-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033519/0001209191-19-033519-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119035218/0001209191-19-035218-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119035222/0001209191-19-035222-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119035225/0001209191-19-035225-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119035227/0001209191-19-035227-index.htm |
| 2019-07-01 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119039793/0001209191-19-039793-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119041022/0001209191-19-041022-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119041033/0001209191-19-041033-index.htm |
| 2019-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119042480/0001209191-19-042480-index.htm |
| 2019-07-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119042806/0001209191-19-042806-index.htm |
| 2019-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119044640/0001209191-19-044640-index.htm |
| 2019-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119044641/0001209191-19-044641-index.htm |
| 2019-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119044643/0001209191-19-044643-index.htm |
| 2019-09-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119048599/0001209191-19-048599-index.htm |
| 2019-09-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119048600/0001209191-19-048600-index.htm |
| 2019-09-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119048602/0001209191-19-048602-index.htm |
| 2019-10-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119052481/0001209191-19-052481-index.htm |
| 2019-10-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119052482/0001209191-19-052482-index.htm |
| 2019-10-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119052768/0001209191-19-052768-index.htm |
| 2019-10-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119053312/0001209191-19-053312-index.htm |
| 2019-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119053798/0001209191-19-053798-index.htm |
| 2019-10-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119054364/0001209191-19-054364-index.htm |
| 2019-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119055321/0001209191-19-055321-index.htm |
| 2019-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119055339/0001209191-19-055339-index.htm |
| 2019-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059179/0001209191-19-059179-index.htm |
| 2019-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059181/0001209191-19-059181-index.htm |
| 2019-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059183/0001209191-19-059183-index.htm |
| 2019-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059185/0001209191-19-059185-index.htm |
| 2019-12-30 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919119062179/0001209191-19-062179-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120002076/0001209191-20-002076-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120002081/0001209191-20-002081-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120006976/0001209191-20-006976-index.htm |
| 2020-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120013095/0001209191-20-013095-index.htm |
| 2020-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120013098/0001209191-20-013098-index.htm |
| 2020-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120013103/0001209191-20-013103-index.htm |
| 2020-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120013106/0001209191-20-013106-index.htm |
| 2020-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120013111/0001209191-20-013111-index.htm |
| 2020-03-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120016942/0001209191-20-016942-index.htm |
| 2020-04-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025306/0001209191-20-025306-index.htm |
| 2020-04-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025307/0001209191-20-025307-index.htm |
| 2020-04-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025308/0001209191-20-025308-index.htm |
| 2020-04-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025311/0001209191-20-025311-index.htm |
| 2020-05-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120029396/0001209191-20-029396-index.htm |
| 2020-05-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120029397/0001209191-20-029397-index.htm |
| 2020-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120031860/0001209191-20-031860-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120034312/0001209191-20-034312-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120034314/0001209191-20-034314-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120035060/0001209191-20-035060-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120035065/0001209191-20-035065-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120035067/0001209191-20-035067-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120035071/0001209191-20-035071-index.htm |
| 2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120036385/0001209191-20-036385-index.htm |
| 2020-06-30 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120039487/0001209191-20-039487-index.htm |
| 2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120039488/0001209191-20-039488-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120040373/0001209191-20-040373-index.htm |
| 2020-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120045254/0001209191-20-045254-index.htm |
| 2020-09-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120049749/0001209191-20-049749-index.htm |
| 2020-10-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120054140/0001209191-20-054140-index.htm |
| 2020-10-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120054142/0001209191-20-054142-index.htm |
| 2020-10-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1346830/000120919120055597/0001209191-20-055597-index.htm |
| 2019-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1346830/000155837019009995/0001558370-19-009995-index.htm |
| 2020-02-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1346830/000155837020001659/0001558370-20-001659-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1346830/000155837020006274/0001558370-20-006274-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1346830/000155837020010201/0001558370-20-010201-index.htm |
| 2018-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1346830/000156459018027483/0001564590-18-027483-index.htm |
| 2019-03-12 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1346830/000156459019007389/0001564590-19-007389-index.htm |
| 2019-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1346830/000156459019016603/0001564590-19-016603-index.htm |
| 2019-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1346830/000156459019030186/0001564590-19-030186-index.htm |
| 2019-04-04 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1346830/999999999519000605/9999999995-19-000605-index.htm |
| 2019-03-21 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1346830/999999999719001683/9999999997-19-001683-index.htm |
| 2020-02-05 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1346830/999999999720000510/9999999997-20-000510-index.htm |
| 2020-02-18 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1346830/999999999720000736/9999999997-20-000736-index.htm |
Cara Therapeutics, Inc (CARA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cara Therapeutics, Inc (CARA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1047%Institutional Ownership: 6872%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-11-15 | Mani Mohindru | CFO & Chief Strategy Officer | Sell | 16,042.00 | 18.50 | 296,777.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919118058944/0001209191-18-058944-index.htm |
| 2018-12-27 | DEREK T CHALMERS | President & CEO | Buy | 38,221.00 | 1,009,613.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919118064402/0001209191-18-064402-index.htm | ||
| 2020-04-21 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 12,894.00 | 15.58 | 200,888.52 | 104,492.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025307/0001209191-20-025307-index.htm |
| 2020-04-17 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Buy | 37,500.00 | 117,386.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025307/0001209191-20-025307-index.htm | ||
| 2019-07-17 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 8,996.00 | 27.50 | 247,390.00 | 119,886.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119042806/0001209191-19-042806-index.htm |
| 2019-03-13 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 16,803.00 | 18.87 | 317,072.61 | 122,779.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119019509/0001209191-19-019509-index.htm |
| 2019-05-29 | Scott Terrillion | Sec'y; Chief Compliance & G.C. | Sell | 2,303.00 | 21.38 | 49,238.14 | 12,416.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033519/0001209191-19-033519-index.htm |
| 2018-12-27 | Mani Mohindru | CFO & Chief Strategy Officer | Buy | 12,526.00 | 12,526.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919118064403/0001209191-18-064403-index.htm | ||
| 2019-07-01 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 20,000.00 | 21.90 | 438,000.00 | 128,882.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119041022/0001209191-19-041022-index.htm |
| 2020-06-04 | Christopher Posner | Director | Buy | 7,200.00 | 13,200.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120035060/0001209191-20-035060-index.htm | ||
| 2020-06-04 | HARRISON M JR BAINS | Director | Buy | 7,200.00 | 13,200.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120035067/0001209191-20-035067-index.htm | ||
| 2020-06-04 | Jeffrey L. Ives | Director | Buy | 7,200.00 | 13,200.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120035065/0001209191-20-035065-index.htm | ||
| 2019-05-29 | Mani Mohindru | CFO & Chief Strategy Officer | Sell | 2,496.00 | 21.39 | 53,389.44 | 13,863.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033517/0001209191-19-033517-index.htm |
| 2019-07-15 | Mani Mohindru | CFO & Chief Strategy Officer | Sell | 37,431.00 | 25.00 | 935,775.00 | 13,863.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119042480/0001209191-19-042480-index.htm |
| 2018-12-03 | Frederique Ph.D. Menzaghi | Sr VP-Research & Development | Sell | 3,000.00 | 18.36 | 55,080.00 | 139,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919118061253/0001209191-18-061253-index.htm |
| 2019-03-12 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 3,197.00 | 17.50 | 55,947.50 | 139,582.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119019509/0001209191-19-019509-index.htm |
| 2018-11-01 | Frederique Ph.D. Menzaghi | Sr VP-Research & Development | Sell | 3,000.00 | 18.77 | 56,310.00 | 142,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919118057307/0001209191-18-057307-index.htm |
| 2019-02-28 | Frederique Ph.D. Menzaghi | Sr VP-Research & Development | Sell | 1,500.00 | 17.50 | 26,250.00 | 142,779.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119015839/0001209191-19-015839-index.htm |
| 2019-02-25 | Frederique Ph.D. Menzaghi | Sr VP-Research & Development | Sell | 2,200.00 | 17.50 | 38,500.00 | 144,279.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119014161/0001209191-19-014161-index.htm |
| 2018-11-01 | Frederique Ph.D. Menzaghi | Sr VP-Research & Development | Buy | 40,000.00 | 2.05 | 82,000.00 | 145,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919118057307/0001209191-18-057307-index.htm |
| 2018-12-28 | Frederique Ph.D. Menzaghi | Sr VP-Research & Development | Sell | 4,300.00 | 12.53 | 53,879.00 | 146,479.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119000406/0001209191-19-000406-index.htm |
| 2019-05-28 | Scott Terrillion | Sec'y; Chief Compliance & G.C. | Buy | 8,333.00 | 14,719.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033519/0001209191-19-033519-index.htm | ||
| 2019-05-29 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 11,397.00 | 21.19 | 241,502.43 | 148,882.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033516/0001209191-19-033516-index.htm |
| 2018-12-27 | Frederique Ph.D. Menzaghi | Sr VP-Research & Development | Buy | 11,779.00 | 150,779.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919118064404/0001209191-18-064404-index.htm | ||
| 2020-02-24 | Joana Goncalves | Chief Medical Officer | Buy | 16,000.00 | 16,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120013103/0001209191-20-013103-index.htm | ||
| 2019-05-28 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Buy | 37,500.00 | 160,279.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033516/0001209191-19-033516-index.htm | ||
| 2018-11-15 | Mani Mohindru | CFO & Chief Strategy Officer | Buy | 16,042.00 | 14.06 | 225,550.52 | 16,042.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919118058944/0001209191-18-058944-index.htm |
| 2019-05-28 | Mani Mohindru | CFO & Chief Strategy Officer | Buy | 8,333.00 | 16,359.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033517/0001209191-19-033517-index.htm | ||
| 2019-12-04 | Scott Terrillion | Sec'y; Chief Compliance & G.C. | Sell | 3,980.00 | 17.05 | 67,859.00 | 16,769.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059185/0001209191-19-059185-index.htm |
| 2019-12-04 | Mani Mohindru | CFO & Chief Strategy Officer | Sell | 4,755.00 | 17.05 | 81,072.75 | 17,441.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059183/0001209191-19-059183-index.htm |
| 2020-06-04 | MARTIN VOGELBAUM | Director | Buy | 14,400.00 | 20,400.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120035071/0001209191-20-035071-index.htm | ||
| 2019-12-02 | Scott Terrillion | Sec'y; Chief Compliance & G.C. | Buy | 8,333.00 | 20,749.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059185/0001209191-19-059185-index.htm | ||
| 2019-12-02 | Mani Mohindru | CFO & Chief Strategy Officer | Buy | 8,333.00 | 22,196.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059183/0001209191-19-059183-index.htm | ||
| 2019-03-13 | Mani Mohindru | CFO & Chief Strategy Officer | Buy | 16,041.00 | 14.06 | 225,536.46 | 24,067.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119019712/0001209191-19-019712-index.htm |
| 2020-02-24 | Scott Terrillion | Sec'y; Chief Compliance & G.C. | Buy | 16,000.00 | 32,769.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120013106/0001209191-20-013106-index.htm | ||
| 2020-10-20 | Joana Goncalves | Chief Medical Officer | Sell | 2,000.00 | 15.00 | 30,000.00 | 33,373.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120055597/0001209191-20-055597-index.htm |
| 2020-06-12 | Joana Goncalves | Chief Medical Officer | Sell | 10,627.00 | 15.20 | 161,530.40 | 35,373.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120036385/0001209191-20-036385-index.htm |
| 2020-04-21 | Scott Terrillion | Sec'y; Chief Compliance & G.C. | Sell | 2,721.00 | 15.56 | 42,338.76 | 38,382.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025308/0001209191-20-025308-index.htm |
| 2020-04-17 | Scott Terrillion | Sec'y; Chief Compliance & G.C. | Buy | 8,334.00 | 41,103.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025308/0001209191-20-025308-index.htm | ||
| 2020-06-10 | Joana Goncalves | Chief Medical Officer | Buy | 30,000.00 | 46,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120036385/0001209191-20-036385-index.htm | ||
| 2019-07-15 | Mani Mohindru | CFO & Chief Strategy Officer | Buy | 37,431.00 | 14.06 | 526,279.86 | 51,294.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119042480/0001209191-19-042480-index.htm |
| 2019-06-04 | Christopher Posner | Director | Buy | 6,000.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119035225/0001209191-19-035225-index.htm | ||
| 2019-06-04 | HARRISON M JR BAINS | Director | Buy | 6,000.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119035218/0001209191-19-035218-index.htm | ||
| 2019-06-04 | Jeffrey L. Ives | Director | Buy | 6,000.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119035222/0001209191-19-035222-index.htm | ||
| 2019-07-01 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 21.75 | 54,375.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119041033/0001209191-19-041033-index.htm |
| 2019-08-01 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 23.24 | 58,100.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119044641/0001209191-19-044641-index.htm |
| 2019-09-03 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 23.31 | 58,275.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119048600/0001209191-19-048600-index.htm |
| 2019-10-01 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 18.21 | 45,525.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119052482/0001209191-19-052482-index.htm |
| 2019-11-01 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 20.68 | 51,700.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119055339/0001209191-19-055339-index.htm |
| 2019-12-02 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 25.83 | 64,575.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059181/0001209191-19-059181-index.htm |
| 2020-01-02 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 16.13 | 40,325.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120002081/0001209191-20-002081-index.htm |
| 2020-02-03 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 16.23 | 40,575.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120006976/0001209191-20-006976-index.htm |
| 2020-03-04 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 16.00 | 40,000.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120016942/0001209191-20-016942-index.htm |
| 2020-04-21 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 16.00 | 40,000.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025311/0001209191-20-025311-index.htm |
| 2020-05-12 | Jeffrey L. Ives | Director | Sell | 2,500.00 | 16.00 | 40,000.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120029396/0001209191-20-029396-index.htm |
| 2020-06-01 | Jeffrey L. Ives | Director | Sell | 1,000.00 | 16.00 | 16,000.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120034312/0001209191-20-034312-index.htm |
| 2019-06-04 | MARTIN VOGELBAUM | Director | Buy | 6,000.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119035227/0001209191-19-035227-index.htm | ||
| 2018-12-28 | Scott Terrillion | Sec'y; Chief Compliance & G.C. | Sell | 3,100.00 | 12.51 | 38,781.00 | 6,386.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119000405/0001209191-19-000405-index.htm |
| 2019-10-25 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 4,000.00 | 19.91 | 79,640.00 | 63,886.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119054364/0001209191-19-054364-index.htm |
| 2019-10-18 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 4,000.00 | 19.33 | 77,320.00 | 67,886.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119053798/0001209191-19-053798-index.htm |
| 2020-06-01 | Jeffrey L. Ives | Director | Buy | 1,000.00 | 9.94 | 9,940.00 | 7,000.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120034312/0001209191-20-034312-index.htm |
| 2019-10-11 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 4,000.00 | 18.70 | 74,800.00 | 71,886.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119053312/0001209191-19-053312-index.htm |
| 2019-10-04 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 4,000.00 | 19.19 | 76,760.00 | 75,886.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119052768/0001209191-19-052768-index.htm |
| 2020-02-24 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Buy | 16,000.00 | 79,886.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120013098/0001209191-20-013098-index.htm | ||
| 2019-09-03 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 20,000.00 | 22.92 | 458,400.00 | 79,886.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119048602/0001209191-19-048602-index.htm |
| 2018-12-28 | Mani Mohindru | CFO & Chief Strategy Officer | Sell | 4,500.00 | 12.55 | 56,475.00 | 8,026.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119000403/0001209191-19-000403-index.htm |
| 2019-03-13 | Mani Mohindru | CFO & Chief Strategy Officer | Sell | 16,041.00 | 19.12 | 306,703.92 | 8,026.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119019712/0001209191-19-019712-index.htm |
| 2019-07-01 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 5.32 | 13,300.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119041033/0001209191-19-041033-index.htm |
| 2019-08-01 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 5.32 | 13,300.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119044641/0001209191-19-044641-index.htm |
| 2019-09-03 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 5.32 | 13,300.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119048600/0001209191-19-048600-index.htm |
| 2019-10-01 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 5.32 | 13,300.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119052482/0001209191-19-052482-index.htm |
| 2019-11-01 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 5.32 | 13,300.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119055339/0001209191-19-055339-index.htm |
| 2019-12-02 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 5.32 | 13,300.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059181/0001209191-19-059181-index.htm |
| 2020-01-02 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 9.94 | 24,850.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120002081/0001209191-20-002081-index.htm |
| 2020-02-03 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 9.94 | 24,850.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120006976/0001209191-20-006976-index.htm |
| 2020-03-04 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 9.94 | 24,850.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120016942/0001209191-20-016942-index.htm |
| 2020-04-21 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 9.94 | 24,850.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025311/0001209191-20-025311-index.htm |
| 2020-05-12 | Jeffrey L. Ives | Director | Buy | 2,500.00 | 9.94 | 24,850.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120029396/0001209191-20-029396-index.htm |
| 2020-01-02 | DEREK T CHALMERS | President & CEO | Sell | 10,000.00 | 16.05 | 160,500.00 | 917,769.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120002076/0001209191-20-002076-index.htm |
| 2019-12-02 | DEREK T CHALMERS | President & CEO | Sell | 10,000.00 | 25.79 | 257,900.00 | 918,468.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059179/0001209191-19-059179-index.htm |
| 2019-12-04 | DEREK T CHALMERS | President & CEO | Sell | 10,699.00 | 17.05 | 182,417.95 | 927,769.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059179/0001209191-19-059179-index.htm |
| 2019-11-01 | DEREK T CHALMERS | President & CEO | Sell | 5,000.00 | 20.79 | 103,950.00 | 928,468.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119055321/0001209191-19-055321-index.htm |
| 2019-10-01 | DEREK T CHALMERS | President & CEO | Sell | 10,000.00 | 18.28 | 182,800.00 | 933,468.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119052481/0001209191-19-052481-index.htm |
| 2019-12-02 | DEREK T CHALMERS | President & CEO | Buy | 20,000.00 | 938,468.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119059179/0001209191-19-059179-index.htm | ||
| 2019-09-03 | DEREK T CHALMERS | President & CEO | Sell | 5,000.00 | 23.26 | 116,300.00 | 943,468.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119048599/0001209191-19-048599-index.htm |
| 2019-03-01 | DEREK T CHALMERS | President & CEO | Sell | 9,792.00 | 17.04 | 166,855.68 | 943,996.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119016647/0001209191-19-016647-index.htm |
| 2019-08-01 | DEREK T CHALMERS | President & CEO | Sell | 10,000.00 | 23.27 | 232,700.00 | 948,468.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119044640/0001209191-19-044640-index.htm |
| 2018-12-27 | Scott Terrillion | Sec'y; Chief Compliance & G.C. | Buy | 9,486.00 | 9,486.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919118064405/0001209191-18-064405-index.htm | ||
| 2020-09-03 | DEREK T CHALMERS | President & CEO | Sell | 3,201.00 | 16.00 | 51,216.00 | 953,220.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120049749/0001209191-20-049749-index.htm |
| 2019-02-01 | DEREK T CHALMERS | President & CEO | Sell | 20,000.00 | 14.99 | 299,800.00 | 953,788.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119007341/0001209191-19-007341-index.htm |
| 2020-08-03 | DEREK T CHALMERS | President & CEO | Sell | 5,000.00 | 16.42 | 82,100.00 | 956,421.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120045254/0001209191-20-045254-index.htm |
| 2019-05-29 | DEREK T CHALMERS | President & CEO | Sell | 5,528.00 | 21.42 | 118,409.76 | 958,468.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033518/0001209191-19-033518-index.htm |
| 2020-07-01 | DEREK T CHALMERS | President & CEO | Sell | 5,000.00 | 17.11 | 85,550.00 | 961,421.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120040373/0001209191-20-040373-index.htm |
| 2019-05-28 | DEREK T CHALMERS | President & CEO | Buy | 20,000.00 | 963,996.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119033518/0001209191-19-033518-index.htm | ||
| 2020-06-03 | DEREK T CHALMERS | President & CEO | Sell | 4,300.00 | 16.01 | 68,843.00 | 966,421.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120034314/0001209191-20-034314-index.htm |
| 2020-02-24 | DEREK T CHALMERS | President & CEO | Buy | 50,000.00 | 967,769.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120013095/0001209191-20-013095-index.htm | ||
| 2020-06-01 | DEREK T CHALMERS | President & CEO | Sell | 700.00 | 16.00 | 11,200.00 | 970,721.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120034314/0001209191-20-034314-index.htm |
| 2018-12-03 | DEREK T CHALMERS | President & CEO | Sell | 20,000.00 | 18.17 | 363,400.00 | 971,392.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919118061248/0001209191-18-061248-index.htm |
| 2020-05-22 | DEREK T CHALMERS | President & CEO | Sell | 371.00 | 16.00 | 5,936.00 | 971,421.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120031860/0001209191-20-031860-index.htm |
| 2020-05-21 | DEREK T CHALMERS | President & CEO | Sell | 3,500.00 | 16.00 | 56,000.00 | 971,792.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120031860/0001209191-20-031860-index.htm |
| 2019-01-04 | DEREK T CHALMERS | President & CEO | Sell | 5,000.00 | 15.04 | 75,200.00 | 973,788.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119001924/0001209191-19-001924-index.htm |
| 2020-05-20 | DEREK T CHALMERS | President & CEO | Sell | 1,200.00 | 16.00 | 19,200.00 | 975,292.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120031860/0001209191-20-031860-index.htm |
| 2020-05-12 | DEREK T CHALMERS | President & CEO | Sell | 4,929.00 | 16.00 | 78,864.00 | 976,492.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120029397/0001209191-20-029397-index.htm |
| 2019-01-02 | DEREK T CHALMERS | President & CEO | Sell | 15,000.00 | 13.13 | 196,950.00 | 978,788.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119001924/0001209191-19-001924-index.htm |
| 2020-04-21 | DEREK T CHALMERS | President & CEO | Sell | 6,348.00 | 15.56 | 98,774.88 | 981,421.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025306/0001209191-20-025306-index.htm |
| 2020-04-17 | DEREK T CHALMERS | President & CEO | Buy | 20,000.00 | 987,769.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919120025306/0001209191-20-025306-index.htm | ||
| 2018-12-28 | DEREK T CHALMERS | President & CEO | Sell | 15,825.00 | 12.53 | 198,287.25 | 993,788.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119000404/0001209191-19-000404-index.htm |
| 2019-08-01 | Frederique Ph.D. Menzaghi | Chief Scientific Off,SVP-R&D | Sell | 20,000.00 | 23.24 | 464,800.00 | 99,886.00 | https://www.sec.gov/Archives/edgar/data/1346830/000120919119044643/0001209191-19-044643-index.htm |